ATOS
Atossa Therapeutics, Inc.Company with tickers: ATOS
CIK
1488039
CUSIP
04962H704
Shares Outstanding
8,611,361
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $9,870,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Research & Development | $4,779,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Operating Income | $-9,870,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Net Income | $-9,589,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Basic) | $-1.11 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Diluted) | $-1.11 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |